(NYSEMKT: PTHS) Pelthos Therapeutics's forecast annual revenue growth rate of 116.01% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.93%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.99%.
Pelthos Therapeutics's revenue in 2026 is $16,795,000.On average, 9 Wall Street analysts forecast PTHS's revenue for 2026 to be $208,187,954, with the lowest PTHS revenue forecast at $185,564,883, and the highest PTHS revenue forecast at $227,009,195. On average, 9 Wall Street analysts forecast PTHS's revenue for 2027 to be $380,082,356, with the lowest PTHS revenue forecast at $333,440,308, and the highest PTHS revenue forecast at $422,798,418.
In 2028, PTHS is forecast to generate $571,616,750 in revenue, with the lowest revenue forecast at $488,231,507 and the highest revenue forecast at $696,577,171.